Markets

LabCorp (LH) Q3 Earnings Surpass Estimates, Tapers View

Laboratory Corporation of America Holdings LH, or LabCorp, reported third-quarter 2019 adjusted earnings per share (EPS) of $2.90, up 5.8% from the year-ago quarter. Also, the bottom line surpassed the Zacks Consensus Estimate by 2.1%.

On a reported basis, net earnings were $2.25 per share, declining 27.4% from the year-earlier figure.

Revenues in the quarter under review grew 3.4% year over year to $2.93 billion. The top line also beat the Zacks Consensus Estimate of $2.91 billion by 0.7%.

The marginal year-over-year improvement was primarily led by 2.8% growth from acquisitions and 2.2% organic growth (which includes the negative impact of Protecting Access to Medicare Act or PAMA of 0.9%), partially offset by 1.3% negative impact of business dispositions and approximately 0.3% adverse foreign currency translation.

Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise

 

Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise

Laboratory Corporation of America Holdings price-consensus-eps-surprise-chart | Laboratory Corporation of America Holdings Quote

Quarter in Detail

LabCorp reports results under two operating segments — LabCorp Diagnostics and Covance Drug Development.

In the third quarter, LabCorp Diagnostics reported revenues of $1.76 billion, reflecting a 0.4% uptick year over year. The upside primarily resulted from 0.9% organic growth and 0.8% favorable contribution from acquisitions, offset by 1.3% headwind from business dispositions. Organic revenue growth in the quarter included a 1.5% negative impact from the implementation of the PAMA.

Excluding business dispositions, the company witnessed 0.7% rise in total volume (measured by requisition) and 1% improvement in revenue per requisition in the third quarter.

Covance Drug Development’s revenues improved 8.7% to $1.18 billion in the third quarter. The upside was primarily attributed to 6% growth from acquisitions and 4.7% organic growth, partially offset by 0.8% adverse impact of foreign currency translation and business disposition of 1.2%.

Gross margin remained flat year over year at 27.9% in the reported quarter. Also, adjusted operating income rose 1.9% year over year to $430.5 million. However, adjusted operating margin contracted 22 bps from the year-ago quarter to 21.5%.

LabCorp exited the third quarter with cash and cash equivalents of $361.1 million compared with $265.4 million at the end of the second quarter. Year to date, operating cash flow was $874.9 million, up from $819 million in the year-ago period. Additionally, free cash flow was at $602.9 million in the quarter, up from $561.4 million a year ago.

In the third quarter, the company returned $100 million to shareholders via share repurchases. LabCorp currently has $950 million of authorization remaining under its existing share buyback plan.

Outlook

The company has revised its 2019 guidance.

It now expects year-over-year revenue growth of 1.5-2% compared with 1-2% mentioned earlier. This includes a projected adverse impact of 1.5% from the disposition of businesses and a negative foreign currency movement of roughly 0.6%. The Zacks Consensus Estimate for revenues is pegged at $11.48 billion for the current year.

Adjusted EPS estimate for 2019 has been narrowed to $11.20-$11.30 from $11.10-$11.40 mentioned earlier, indicating 1.6-2.5% rise from the 2018 adjusted EPS figure. The Zacks Consensus Estimate of $11.29 for the same is close to the high end of the company’s guidance.

Free cash flow is predicted to be $950-$1.05 billion (unchanged).

Our Take

LabCorp exited the third quarter on a strong note, with better-than-expected results. While increasing acquisitions and a favorable mix contributed to its Diagnostics business in the quarter, the disposition of certain businesses and the implementation of PAMA dented the company’s growth.

However, Covance Drug Development delivered year-over-year growth. Here, synergies from acquisitions and organic growth were partially negated by the impact of foreign currency translation.

Zacks Rank & Stocks to Consider

Currently, LabCorp carries a Zacks Rank #4 (Sell). Some better-ranked stocks from the broader medical space are Owens & Minor, Inc OMI, Surmodics, Inc SRDX and Organigram Holdings Inc OGI.

Owens & Minor is scheduled to release third-quarter 2019 results on Oct 30. The Zacks Consensus Estimate for the quarter’s adjusted EPS is pegged at 65 cents and the same for revenues is pinned at $9.9 billion. The stock currently sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Surmodics is scheduled to release fourth-quarter 2019 results on Nov 8. The Zacks Consensus Estimate for its adjusted EPS is pinned at 69 cents and the same for revenues is pegged at $97.8 million. The stock currently sports a Zacks Rank #1.

Organigram is expected to release fourth-quarter 2019 results on Nov 25. The Zacks Consensus Estimate for its adjusted EPS is pegged at 5 cents and the same for revenues is pinned at $71.2 million. The stock presently has a Zacks Rank of 2 (Buy).

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>


Click to get this free report

Surmodics, Inc. (SRDX): Free Stock Analysis Report

Owens & Minor, Inc. (OMI): Free Stock Analysis Report

Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report

Organigram Holdings Inc. (OGI): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More